{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:41Z","timestamp":1789014581265,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["POIR.04.04.00-00-5EC2\/18-00"],"award-info":[{"award-number":["POIR.04.04.00-00-5EC2\/18-00"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001870","name":"Fundacja na rzecz Nauki Polskiej","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001870","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["952304"],"award-info":[{"award-number":["952304"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejphar.2021.174505","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T03:35:19Z","timestamp":1631590519000},"page":"174505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["7-[[(4-methyl-2-pyridinyl)amino](2-pyridinyl)methyl]-8-quinolinol (compound 30666) inhibits enhancer activity and reduces B-cell lymphoma growth \u2013 A question of specificity"],"prefix":"10.1016","volume":"910","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2066-2581","authenticated-orcid":false,"given":"Marta El\u017cbieta","family":"Kasprzyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"\u0141osiewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9720-7881","authenticated-orcid":false,"given":"Marta","family":"Podralska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1286-7261","authenticated-orcid":false,"given":"Marta","family":"Kazimierska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Sura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-2114","authenticated-orcid":false,"given":"Agnieszka","family":"Dzikiewicz-Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174505_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00636","article-title":"Targeting the Bcl-2 family in B cell lymphoma","author":"Adams","year":"2019","journal-title":"Front. Oncol"},{"key":"10.1016\/j.ejphar.2021.174505_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00377","article-title":"Diversity and emerging roles of enhancer RNA in regulation of gene expression and cell fate","author":"Arnold","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2021.174505_bib3","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1158\/0008-5472.CAN-12-4300","article-title":"KDM4\/JMJD2 histone demethylases: epigenetic regulators in cancer cells","volume":"73","author":"Berry","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejphar.2021.174505_bib4","doi-asserted-by":"crossref","DOI":"10.21873\/anticanres.11020","article-title":"Strong KDM4B and KDM4D expression associates with radioresistance and aggressive phenotype in classical hodgkin lymphoma","volume":"36","author":"Bur","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejphar.2021.174505_bib5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.molonc.2013.04.006","article-title":"Erroneous class switching and false VDJ recombination: molecular dissection of t(8;14)\/MYC-IGH translocations inBurkitt-type lymphoblastic leukemia\/B-cell lymphoma","volume":"7","author":"Burmeister","year":"2013","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejphar.2021.174505_bib6","series-title":"Molecular Biology of B Cells","article-title":"Transcription of immunoglobulin genes","author":"Calame","year":"2004"},{"key":"10.1016\/j.ejphar.2021.174505_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2013.01.038","article-title":"Modification of enhancer chromatin: what, how, and why?","author":"Calo","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2021.174505_bib8","first-page":"1","article-title":"Targeting oncogenic Myc as a strategy for cancer treatment","author":"Chen","year":"2018","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejphar.2021.174505_bib9","doi-asserted-by":"crossref","first-page":"21931","DOI":"10.1073\/pnas.1016071107","article-title":"Histone H3K27ac separates active from poised enhancers and predicts developmental state","volume":"107","author":"Creyghton","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2021.174505_bib10","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejphar.2021.174505_bib11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/15384047.2018.1538615","article-title":"Discovery platform for inhibitors of IgH gene enhancer activity","volume":"20","author":"Dolloff","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejphar.2021.174505_bib12","series-title":"Functional Long-Range Interactions of the IgH 3\u2032 Enhancers with the Bcl-2 Promoter Region in T(14;18) Lymphoma Cells. Oncogene","author":"Duan","year":"2008"},{"key":"10.1016\/j.ejphar.2021.174505_bib13","series-title":"Impact of heterozygous c.657-661del, p.I171V and p.R215W mutations in NBN on nibrin functions. Mutagenesis","author":"Dzikiewicz-Krawczyk","year":"2012"},{"key":"10.1016\/j.ejphar.2021.174505_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1649.1649","article-title":"SIRT1 expression is higher in human follicular lymphoma and correlates with Ki67 and bcl-6 overexpression","volume":"124","author":"Frazzi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2021.174505_bib15","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.12535","article-title":"The IgH 3\u2019 regulatory region and c-myc-induced B-cell lymphomagenesis","author":"Ghazzaui","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2021.174505_bib16","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2019000845","article-title":"E\u03bc and 3\u2019RR transcriptional enhancers of the IgH locus cooperate to promote c-myc-induced mature B-cell lymphomas","author":"Ghazzaui","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejphar.2021.174505_bib17","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2004-12-4621","article-title":"Oncogenes as molecular targets in lymphoma","author":"Hachem","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2021.174505_bib18","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/cancers13061292","article-title":"Targeting BCL-2 in cancer: advances, challenges, and perspectives","volume":"13","author":"Hafezi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2021.174505_bib19","series-title":"Molecular Biology of B Cells","article-title":"Transcriptional regulation of early B cell development","author":"Hagman","year":"2015"},{"key":"10.1016\/j.ejphar.2021.174505_bib20","doi-asserted-by":"crossref","DOI":"10.4161\/mco.29904","article-title":"Chromosomal rearrangements in cancer: detection and potential causal mechanisms","author":"Hasty","year":"2014","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.ejphar.2021.174505_bib21","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1158\/0008-5472.CAN-05-3617","article-title":"Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes","volume":"66","author":"Heltweg","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejphar.2021.174505_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020008743","article-title":"KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas","author":"Heward","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2021.174505_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1631\/jzus.B1900148","article-title":"Role of SIRT1 in hematologic malignancies","volume":"20","author":"Huang","year":"2019","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"10.1016\/j.ejphar.2021.174505_bib24","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115030","article-title":"Novel epigenetic vulnerabilities for diffuse large B-cell lymphoma","volume":"132","author":"Jha","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2021.174505_bib25","series-title":"Histone H3K4me1 and H3K27ac Play Roles in Nucleosome Depletion and eRNA Transcription. bioRxiv","author":"Kang","year":"2021"},{"key":"10.1016\/j.ejphar.2021.174505_bib26","first-page":"1","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejphar.2021.174505_bib27","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.3390\/cancers13133270","article-title":"Enhancing B-cell malignancies-on repurposing enhancer activity towards cancer","volume":"13","author":"Kasprzyk","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2021.174505_bib28","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1096\/fj.201902584R","article-title":"Advances in histone demethylase KDM4 as cancer therapeutic targets","volume":"34","author":"Lee","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.ejphar.2021.174505_bib29","first-page":"1","article-title":"Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2021.174505_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1947601912475079","article-title":"The roles of SIRT1 in cancer","volume":"4","author":"Lin","year":"2013","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ejphar.2021.174505_bib31","article-title":"Histone deacetylase inhibitor Trichostatin A reduces anti-DNA autoantibody production and represses IgH gene transcription","author":"Lu","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2021.174505_bib32","first-page":"1","article-title":"A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival","author":"Massett","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejphar.2021.174505_bib33","series-title":"CELL CYCLE ACTIVATION by C-Myc IN A BURKITT LYMPHOMA MODEL CELL LINE","author":"Pajic","year":"2000"},{"key":"10.1016\/j.ejphar.2021.174505_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)00601-9","article-title":"Cis-regulatory elements and epigenetic changes control genomic reaarangements of the IgH locus","volume":"99","author":"Perlot","year":"2008","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.ejphar.2021.174505_bib35","series-title":"Advances in Immunology","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-387663-8.00002-8","article-title":"The IgH locus 3\u2019 regulatory region: pulling the strings from behind","author":"Pinaud","year":"2011"},{"key":"10.1016\/j.ejphar.2021.174505_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0076-6879(08)01606-6","article-title":"DNA damage response and apoptosis","volume":"446","author":"Plesca","year":"2008","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.ejphar.2021.174505_bib37","series-title":"3\u2019RR Targeting in Lymphomagenesis: A Promising Strategy? Cell Cycle","author":"Saintamand","year":"2015"},{"key":"10.1016\/j.ejphar.2021.174505_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41594-020-0446-0","article-title":"Enhancer RNAs are an important regulatory layer of the epigenome","author":"Sartorelli","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejphar.2021.174505_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.molimm.2020.02.002","article-title":"Aryl hydrocarbon receptor-induced activation of the human IGH hs1.2 enhancer: mutational analysis of putative regulatory binding motifs","author":"Snyder","year":"2020","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ejphar.2021.174505_bib40","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.103.059493","article-title":"2,3,7,8-Tetrachlorodibenzo-p-dioxin, an exogenous modulator of the 3\u2032\u03b1 immunoglobulin heavy chain enhancer in the CH12.LX mouse cell line","author":"Sulentic","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2021.174505_bib41","series-title":"Archives of Pathology and Laboratory Medicine","first-page":"1148","article-title":"Chromosomal translocations involved in non-Hodgkin lymphomas","author":"Vega","year":"2003"},{"key":"10.1016\/j.ejphar.2021.174505_bib42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1947601912473826","article-title":"Emerging roles of SIRT1 in cancer drug resistance","volume":"4","author":"Wang","year":"2013","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ejphar.2021.174505_bib43","series-title":"Advances in Experimental Medicine and Biology","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-15-3532-1_1","article-title":"B cell development and maturation","author":"Wang","year":"2020"},{"key":"10.1016\/j.ejphar.2021.174505_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2015.02.012","article-title":"The aryl hydrocarbon receptor regulates an essential transcriptional element in the immunoglobulin heavy chain gene","author":"Wourms","year":"2015","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ejphar.2021.174505_bib45","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s11670-011-0160-x","article-title":"Clinical impact of t(14;18) in diffuse large B-cell lymphoma","volume":"23","author":"Zhang","year":"2011","journal-title":"Chinese J. Cancer Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:57:56Z","timestamp":1757977076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921006592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":45,"alternative-id":["S0014299921006592"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174505","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"7-[[(4-methyl-2-pyridinyl)amino](2-pyridinyl)methyl]-8-quinolinol (compound 30666) inhibits enhancer activity and reduces B-cell lymphoma growth \u2013 A question of specificity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"174505"}}